{"id":"https://openalex.org/W17671018","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4683","title":"Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC)","display_name":"Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC)","publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W17671018","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4683","mag":"17671018"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2005.23.16_suppl.4683","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4683","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4683","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113456684","display_name":"M. Nakabayashi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Nakabayashi","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017334876","display_name":"Meredith M. Regan","orcid":"https://orcid.org/0000-0002-2428-6109","observed_orcids":["https://orcid.org/0000-0002-2428-6109"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. M. Regan","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112711362","display_name":"Deborah Lifsey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Lifsey","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031415193","display_name":"Carolyn P. Evan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. P. Evan","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056766924","display_name":"Philip W. Kantoff","orcid":"https://orcid.org/0000-0001-7275-0597","observed_orcids":["https://orcid.org/0000-0001-7275-0597"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. W. Kantoff","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023517416","display_name":"Mary\u2010Ellen Taplin","orcid":"https://orcid.org/0000-0002-3384-0300","observed_orcids":["https://orcid.org/0000-0002-3384-0300"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. E. Taplin","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073246821","display_name":"Oliver A. Sartor","orcid":"https://orcid.org/0000-0002-8777-7343","observed_orcids":["https://orcid.org/0000-0002-8777-7343"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"O. Sartor","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078027978","display_name":"William K. Oh","orcid":"https://orcid.org/0000-0001-5113-8147","observed_orcids":["https://orcid.org/0000-0001-5113-8147"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. K. Oh","raw_affiliation_strings":["Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Inst and Harvard Medcl Sch, Boston, MA; Stanley Scott Cancer Ctr, LSU, New Orleans, LA","institution_ids":["https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I136199984"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"23","issue":"16_suppl","first_page":"4683","last_page":"4683"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11146","display_name":"Hormonal and reproductive studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nilutamide","display_name":"nilutamide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9900000095367432},{"id":"https://openalex.org/keywords/androgen-receptor-antagonists","display_name":"androgen receptor antagonists","score":0.902999997138977},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.8669999837875366},{"id":"https://openalex.org/keywords/gnrh-agonist","display_name":"GnRH agonist","score":0.8339999914169312},{"id":"https://openalex.org/keywords/orchiectomy","display_name":"orchiectomy","score":0.9919999837875366},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.5759999752044678},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.6669999957084656},{"id":"https://openalex.org/keywords/history-of-chemotherapy","display_name":"history of chemotherapy","score":0.4169999957084656},{"id":"https://openalex.org/keywords/patient-acceptance-of-treatment","display_name":"patient acceptance of treatment","score":0.4410000145435333},{"id":"https://openalex.org/keywords/toxicity-profile","display_name":"toxicity profile","score":0.4169999957084656}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9183241128921509},{"id":"https://openalex.org/C2778311097","wikidata":"https://www.wikidata.org/wiki/Q5903784","display_name":"Hormonal therapy","level":4,"score":0.6695870161056519},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.653131902217865},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5643765926361084},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5052829384803772},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4867229759693146},{"id":"https://openalex.org/C2781406297","wikidata":"https://www.wikidata.org/wiki/Q409450","display_name":"Prostate-specific antigen","level":4,"score":0.4789567291736603},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4474961459636688},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.43521153926849365},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4162895083427429},{"id":"https://openalex.org/C2779322244","wikidata":"https://www.wikidata.org/wiki/Q574820","display_name":"Antiandrogen","level":4,"score":0.41271668672561646},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33652353286743164},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.21652883291244507}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2005.23.16_suppl.4683","doi":"https://doi.org/10.1200/jco.2005.23.16_suppl.4683","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2005.23.16_suppl.4683","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2062865195","https://openalex.org/W2138633329","https://openalex.org/W2065112594","https://openalex.org/W1972988759","https://openalex.org/W179206417","https://openalex.org/W4248330524","https://openalex.org/W2077528901","https://openalex.org/W2604144000","https://openalex.org/W116367892","https://openalex.org/W1964850437"],"abstract_inverted_index":{"4683":[0],"Background:":[1],"Treatment":[2],"options":[3],"are":[4],"limited":[5],"for":[6],"patients":[7,42,52,68,114,150,182,313],"with":[8,17,43,53,58,272,314,316],"androgen":[9],"independent":[10],"prostate":[11],"cancer":[12],"(AIPC).":[13],"Secondary":[14],"hormonal":[15,39,62,95,233,283,310],"therapy":[16,40,63,139,311],"antiandrogens":[18],"has":[19],"advantages,":[20],"including":[21],"low":[22],"toxicity,":[23],"oral":[24],"administration":[25],"and":[26,97,127,135,140,170,197],"high":[27],"patient":[28,132,162],"acceptance.":[29],"We":[30],"have":[31,85,269],"evaluated":[32],"the":[33,110,128],"activity":[34],"of":[35,77,88,92,100,112,125,137,149,156,179,190,217,248,256,260],"nilutamide":[36,59,78,143,152,195,240],"as":[37,60,228,280],"secondary":[38,61,94,309],"in":[41,64,121,237,312],"AIPC.":[44],"Methods:":[45],"Retrospective":[46],"study":[47],"was":[48,107,166,173],"focused":[49],"on":[50,244],"45":[51,180],"AIPC":[54,315],"who":[55,115],"were":[56,81,102,144,224,241,265,294],"treated":[57],"two":[65],"institutions.":[66],"All":[67],"had":[69,116,203,211],"a":[70,117,154,204,212,317],"detectable":[71],"prostate-specific":[72],"antigen":[73],"(PSA)":[74],"at":[75,153,164,252],"initiation":[76,255],"therapy,":[79,196,250],"but":[80],"not":[82],"required":[83],"to":[84,108,142,215,230,239,268,296,305],"radiographic":[86],"evidence":[87],"disease.":[89],"Any":[90],"number":[91],"prior":[93,98,261],"therapies":[96],"history":[99],"chemotherapy":[101],"allowed.":[103],"The":[104,147,288],"primary":[105],"endpoint":[106],"determine":[109],"%":[111],"evaluable":[113,181],"\u2265":[118,207],"50%":[119,208],"decline":[120,189,206],"PSA.":[122],"Adverse":[123],"effects":[124,293],"treatment,":[126],"relationship":[129],"between":[130],"baseline":[131],"characteristics,":[133],"type":[134,247,259],"duration":[136],"previous":[138],"response":[141,238],"also":[145],"assessed.":[146],"majority":[148],"received":[151,270],"dose":[155],"150":[157],"mg/day":[158],"orally.":[159],"Results:":[160],"Median":[161],"age":[163],"diagnosis":[165,253],"64":[167],"(range":[168,176,220],"43\u201388),":[169],"median":[171,213],"PSA":[172,188,205,251],"17.0":[174],"ng/ml":[175],"2.5\u20132356).":[177],"Thirty":[178],"(66.6%;":[183],"95%":[184,200],"CI":[185,201],"51.1\u201380.0%)":[186],"experienced":[187],"any":[191],"degree":[192],"after":[193],"starting":[194],"18":[198],"(40%;":[199],"25.7\u201355.7%)":[202],"(Responders).":[209],"Responders":[210,264],"time":[214],"progression":[216],"4.4":[218],"months":[219],"0.31+-44.7+).":[221],"Nilutamide":[222,303],"responses":[223],"seen":[225],"whether":[226],"used":[227],"2nd":[229],"5th":[231],"line":[232,282],"therapy.":[234,263],"No":[235],"differences":[236],"observed":[242],"based":[243],"clinical":[245],"stage,":[246],"local":[249],"or":[254,258,278,324,327],"nilutamide,":[257],"antiandrogen":[262],"more":[266],"likely":[267],"monotherapy":[271],"luteinizing":[273],"hormone":[274,276],"releasing":[275],"agonist":[277],"orchiectomy":[279],"first":[281],"treatment":[284],"than":[285],"non-responders":[286],"(p=0.02).":[287],"most":[289],"common":[290],"reversible":[291],"adverse":[292],"mild":[295,318],"moderate":[297],"visual":[298],"adaptation":[299],"alterations":[300],"(20%).":[301],"Conclusions:":[302],"appears":[304],"be":[306],"an":[307],"effective":[308],"toxicity":[319],"profile.":[320],"Author":[321],"Disclosure":[322],"Employment":[323],"Leadership":[325],"Consultant":[326],"Advisory":[328],"Role":[329],"Stock":[330],"Ownership":[331],"Honoraria":[332],"Research":[333],"Funding":[334],"Expert":[335],"Testimony":[336],"Other":[337],"Remuneration":[338],"Aventis":[339]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}